[1]孙黎, 刘晓琰, 费艳秋. 伊曲康唑制剂的临床应用[J]. 医药导报, 2002, 21(002):99-101.[2]曾正陪. 应重视对原发性醛固酮增多症的规范化诊断治疗 [J] . 中华内科杂志,2020,59 (1): 1-4.[3]Hoffmann WJ, McHardy I, Thompson GR 3rd. Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation. Mycoses. 2018 May;61(5):337-339.[4]Denolle T, Azizi M, Massart C, Zennaro MC. HTA sous itraconazole : une nouvelle cause d'HTA iatrogène [Itraconazole: a new drug-related cause of hypertension]. Ann Cardiol Angeiol (Paris). 2014 Jun;63(3):213-5.[5]Beck KR, Telisman L, van Koppen CJ, Thompson GR 3rd, Odermatt A. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals. J Steroid Biochem Mol Biol. 2020 May;199:105605.[6]Brandi SL, Feltoft CL, Serup J, et al. BMJ Case Rep 2021;14:e243191[7]Funder JW. Apparent mineralocorticoid excess. J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):151-153. doi: 10.1016/j.jsbmb.2016.03.010. Epub 2016 Mar 5. PMID: 26956190.